MAIA Biotechnology announces common stock offering, no amount given

MAIA Biotechnology (MAIA) announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by the company. MAIA intends to use the net proceeds from the offering to conduct clinical trials and for working capital and general corporate purposes. Konik Capital Partners, a division of T.R. Winston & Company, is acting as the sole book-running manager for the offering.